- 20 May 2013
DOCS Launches New Feature Rich Website
The new, modern design includes a range of exciting new features that enhance the user experience for candidates and clients:
- 02 May 2013
ICON and DIA Deliver Webinar on Optimising Development of New Alzheimer’s Therapies
ICON today announced the second in its four-part Solution Provider educational webinar series in collaboration with DIA
- 25 April 2013
ICON Reports First Quarter 2013 Revenue of $317 Million, up 26% year on year and non-GAAP EPS of 36c
ICON today reported its financial results for the first quarter ended March 31, 2013. For the first quarter, net revenues grew 26% year on year to $316.8 million from $252.3 million in Q1 2012.
- 24 April 2013
ICON Wins ‘Partnership Pioneers of the Year’ Award in Recognition of Global Partnership with Pfizer
ICON today announced that is has received the 2013 “Partnership Pioneers of the Year” award in recognition of its strategic partnership with Pfizer and PAREXEL
- 17 April 2013
ICON plc and UCD Smurfit School launch the ICON Business Academy
ICON, in conjunction with University College Dublin (UCD), today announced the launch of the ICON Business Academy
- 21 March 2013
ICON Launches New ICON Signature Series to Share Expertise and Insight into Clinical Development
New thought leadership program offers expert insight into value-driven strategies for clinical development.
- 21 February 2013
ICON Announces Appointment of Professor William Hall to Board of Directors
ICON today announced the appointment of Professor William Hall as a non-executive director
- 19 February 2013
ICON Reports Fourth Quarter 2012 Revenue of $300 Million, up 24% year on year, EPS of 34c and Full Year revenue of $1.12 billion, EPS of $1.00.
- 11 February 2013
ICON and DIA Collaborate to Deliver New Educational Product
ICON to share industry insights on oncology, technology, biomarkers and late phase development
- 04 February 2013
ICON To Acquire Clinical Trial Services Division of Cross Country Healthcare Inc
ICON today announced that it has agreed, subject to certain closing conditions, to acquire the Clinical Trial Services Division of Cross Country Healthcare, Inc. (NASDAQ:CCRN), for a cash consideration of $52 million, plus an earn-out of up to $3.75 million related to certain performance-based milestones
